Big news this week for men with prostate cancer (and their families) who are using hormone therapy: It may not actually work. Researchers at the Cancer Institute of New Jersey followed almost 20,000 men age 66 and older for an average of 18 months and found that those treated with androgen deprivation therapy, which involves taking medication (Lupron, Viadur, Eligard, or Zoladex) to eliminate testosterone production, had no better survival rate than those treated with conservative management. (Conservative management, also called "watchful waiting," means essentially doing nothing while carefully monitoring for disease progression.)
The study, published in last week's Journal of the American Medical Association (JAMA), got lots of oncologists talking because in the past decade, hormone therapy has become a popular alternative to surgery, radiation, or conservative management... Read more


